

**BETH C. DRAIN, CA CSR NO. 7152**

BEFORE THE  
INDEPENDENT CITIZENS' OVERSIGHT COMMITTEE AND THE  
APPLICATION REVIEW SUBCOMMITTEE  
TO THE  
CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE  
ORGANIZED PURSUANT TO THE  
CALIFORNIA STEM CELL RESEARCH AND CURES ACT  
REGULAR MEETING

LOCATION: VIA ZOOM

DATE: JULY 22, 2020  
1 P.M.

REPORTER: BETH C. DRAIN, CA CSR  
CSR. NO. 7152

FILE NO.: 2020-16

**BETH C. DRAIN, CA CSR NO. 7152**

**I N D E X**

<b>ITEM DESCRIPTION</b>	<b>PAGE NO.</b>
<b>OPEN SESSION</b>	
1. CALL TO ORDER.	3
2. ROLL CALL.	3
<b>ACTION ITEMS</b>	
3. CONSIDERATION OF AMENDMENTS TO THE CLIN AND DISC PROGRAM ANNOUNCEMENTS.	7
4. APPOINTMENT AND REAPPOINTMENT OF SCIENTIFIC MEMBERS TO THE GRANTS WORKING GROUP.	14
<b>DISCUSSION ITEMS</b>	
5. UPDATE ON DONATIONS RECEIVED BY CIRM.	16
6. PUBLIC COMMENT.	NONE
7. ADJOURNMENT	18

**BETH C. DRAIN, CA CSR NO. 7152**

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

JULY 22, 2020; 1 P.M.

CHAIRMAN THOMAS: WELCOME TO THE ICOC AND APPLICATION REVIEW SUBCOMMITTEE. ONCE AGAIN ON ZOOM AS WE WILL BE FOR THE FORESEEABLE FUTURE. MARIA, WILL YOU PLEASE CALL THE ROLL.

MS. BONNEVILLE: SURE. GEORGE BLUMENTHAL.

DR. BLUMENTHAL: HERE.

MS. BONNEVILLE: LINDA BOXER. ALLISON BRASHEAR.

DR. BRASHEAR: HERE.

MS. BONNEVILLE: DEBORAH DEAS.

DR. DEAS: HERE.

MS. BONNEVILLE: ANNE-MARIE DULIEGE.

DR. DULIEGE: YES.

MS. BONNEVILLE: YSABEL DURON.

MS. DURON: HERE.

MS. BONNEVILLE: JUDY GASSON.

DR. GASSON: HERE.

MS. BONNEVILLE: DAVID HIGGINS.

DR. HIGGINS: HERE.

MS. BONNEVILLE: STEPHEN JUELSGAARD.

MR. JUELSGAARD: HERE.

MS. BONNEVILLE: LINDA MALKAS.

DR. MALKAS: HERE.

**BETH C. DRAIN, CA CSR NO. 7152**

1 MS. BONNEVILLE: DAVE MARTIN.  
2 DR. MARTIN: HERE.  
3 MS. BONNEVILLE: SHLOMO MELMED.  
4 DR. MELMED: HERE.  
5 MS. BONNEVILLE: LAUREN MILLER-ROGEN.  
6 MS. MILLER-ROGEN: HERE.  
7 MS. BONNEVILLE: ADRIANA PADILLA.  
8 DR. PADILLA: HERE.  
9 MS. BONNEVILLE: JOE PANETTA.  
10 MR. PANETTA: HERE.  
11 MS. BONNEVILLE: FRANCISCO PRIETO. HE'S  
12 LOGGING ON.  
13 ROBERT QUINT. AL ROWLETT. I THOUGHT I  
14 SAW DR. QUINT ON HERE SOMEWHERE. IS HE ON MUTE?  
15 DR. QUINT, YOU'RE ON MUTE. I'M GOING TO UNMUTE YOU.  
16 NO. OKAY.  
17 AL ROWLETT. SUZANNE SANDMEYER.  
18 DR. SANDMEYER: HERE.  
19 MS. BONNEVILLE: JEFF SHEEHY.  
20 MR. SHEEHY: HERE.  
21 MS. BONNEVILLE: OSWALD STEWARD. JONATHAN  
22 THOMAS.  
23 CHAIRMAN THOMAS: HERE.  
24 MS. BONNEVILLE: ART TORRES.  
25 MR. TORRES: HERE.

**BETH C. DRAIN, CA CSR NO. 7152**

1 MS. BONNEVILLE: KRISTINA VUORI.

2 DR. VUORI: HERE.

3 MS. BONNEVILLE: DIANE WINOKUR.

4 MS. WINOKUR: HERE.

5 MS. BONNEVILLE: KEITH YAMAMOTO. DOUG  
6 ZIEDONIS.

7 DR. ZIEDONIS: HERE.

8 MS. BONNEVILLE: THANK YOU. WE HAVE A  
9 QUORUM, J.T.

10 CHAIRMAN THOMAS: THANK YOU, MARIA. TO  
11 START WITH, AS YOU MAY RECALL, KEN BURTIS' LAST  
12 MEETING AS REPRESENTATIVE ON THE BOARD FROM UC DAVIS  
13 WAS IN JUNE. WE NOW HAVE A NEW MEMBER AND NEW  
14 ALTERNATE WHO ARE BOTH ON THE CALL TODAY. AND I'M  
15 GOING TO INTRODUCE BOTH AND ASK THEM TO SAY A FEW  
16 WORDS OF INTRODUCTION.

17 THE MEMBER FROM UC DAVIS IS DEAN ALLISON  
18 BRASHEAR. ALLISON, COULD YOU SAY A FEW WORDS  
19 PLEASE.

20 DR. BRASHEAR: THANK YOU SO MUCH. AND  
21 THANK YOU FOR THE WARM WELCOME. SO I AM A  
22 NEUROLOGIST BY TRAINING, AND I'M THE NEW DEAN AT UC  
23 DAVIS. I'VE BEEN HERE A YEAR EXACTLY TODAY. I COME  
24 FROM NORTH CAROLINA WHERE I WAS THE CHAIR OF  
25 NEUROLOGY FOR 15 YEARS AT WAKE FOREST, AND PRIOR TO

**BETH C. DRAIN, CA CSR NO. 7152**

1 THAT, I TRAINED AT INDIANA UNIVERSITY SCHOOL OF  
2 MEDICINE IN INDIANAPOLIS.

3 MY PERSONAL RESEARCH INTERESTS ARE IN RARE  
4 DISEASES, SPECIFICALLY THOSE THAT AFFECT A VERY RARE  
5 GENETICS POPULATION, AND THEN A LARGE AMOUNT OF WORK  
6 IN CLINICAL TRIALS. I'M REALLY THRILLED TO BE HERE.  
7 I THINK THE WORK THAT HAS GONE ON HERE IS JUST  
8 GROUNDBREAKING AND REALLY SPEAKS SO MUCH ABOUT  
9 EVERYTHING THAT CALIFORNIA BRINGS TO PATIENTS SUCH  
10 AS NEUROLOGY PATIENTS. SO I'M THRILLED TO BE HERE.  
11 THANK YOU SO MUCH.

12 CHAIRMAN THOMAS: THANK YOU, DR.  
13 BRASHEAR. AND OUR ALTERNATE FROM UC DAVIS, WHO'S  
14 NOT A STRANGER TO CIRM, IS DR. JIM KOVACH. JIM,  
15 COULD YOU SAY A FEW WORDS PLEASE.

16 DR. KOVACH: YES. THANKS, J.T.

17 MY NAME IS JIM KOVACH. I'M A PHYSICIAN  
18 ATTORNEY WHO BEGAN WORKING WITH CIRM BACK WHEN I WAS  
19 AT THE BUCK INSTITUTE FOR RESEARCH AND AGING MANY  
20 YEARS AGO GENERAL AND CURRENTLY WORK WITH ALLISON  
21 PRIMARILY ON SPECIFIC PROJECTS. I'M A MEMBER OF THE  
22 ALPHA STEM CELL CLINIC TEAM THAT'S VERY SUCCESSFUL  
23 HERE AT UC DAVIS AND WORKING WITH HER ON AGGIE  
24 SQUARE, A MILLION SQUARE FOOT PHASE 1 RESEARCH AND  
25 INNOVATION DISTRICT THAT'S GOING TO BE REPRESENTED

**BETH C. DRAIN, CA CSR NO. 7152**

1 BY REALLY STRONG INDUSTRY RESEARCH RELATIONSHIPS,  
2 INCLUDING CELL AND GENE THERAPY. SO EXCITED TO BE A  
3 GUEST AND LOOK FORWARD TO SUPPORTING EFFORTS.

4 CHAIRMAN THOMAS: THANK YOU VERY MUCH.  
5 AND JUST FOR SPORTS FANS ON THE CALL, JIM, YOU MIGHT  
6 GIVE A LITTLE ADDITIONAL BACKGROUND PREDATING ALL OF  
7 WHAT YOU JUST SAID.

8 DR. KOVACH: YES. I CAME INTO NFL. I WAS  
9 ACTUALLY A MEDICAL STUDENT AT THE UNIVERSITY OF  
10 KENTUCKY WHEN I WAS DRAFTED AND HAD THE CHANCE TO  
11 WORK MY WAY THROUGH MEDICAL SCHOOL WHILE PLAYING FOR  
12 THE NEW ORLEANS SAINTS. AND THEN MY LAST YEAR AS A  
13 PHYSICIAN WAS WITH THE 49ERS. ACTUALLY HAD A CHANCE  
14 TO WORK WITH MANY OF THE FORMER NINERS LIKE RONNIE  
15 LOTT LOT AND ROGER CRAIG WHO ARE INTERESTED  
16 INNOVATION AND NEW TECHNOLOGIES. AND IT'S  
17 BEEN -- THAT WAS A LOT OF FUN, BUT A LONG TIME AGO.

18 CHAIRMAN THOMAS: THANK YOU BOTH VERY  
19 MUCH. WE ARE ABSOLUTELY DELIGHTED TO HAVE YOU ON  
20 BOARD AND LOOK FORWARD TO WORKING WITH YOU AS WE  
21 HEAD INTO THE FUTURE HERE.

22 SO WITHOUT FURTHER ADO, WE'LL GO ON TO THE  
23 ACTION ITEMS. NO. 1 ACTION ITEM IS CONSIDERATION OF  
24 AMENDMENTS TO THE CLIN AND DISC PROGRAM  
25 ANNOUNCEMENTS. WE'RE GOING TO HAVE A PRESENTATION

**BETH C. DRAIN, CA CSR NO. 7152**

1 BY DR. SAMBRANO.

2 DR. SAMBRANO: THANK YOU, MR. CHAIRMAN.  
3 SO, DOUG, CAN YOU GET THE PRESENTATION UP? OKAY.  
4 GREAT. THANK YOU VERY MUCH.

5 SO GOOD AFTERNOON, MEMBERS OF THE BOARD,  
6 MEMBERS OF THE PUBLIC, AND COLLEAGUES. SO I'M HERE  
7 TO PRESENT AMENDMENTS TO THE DISC2 AND CLIN2  
8 CONCEPTS SPECIFICALLY. SO JUST AS BACKGROUND, AT  
9 THE LAST MEETING OF THE GOVERNING BOARD, WHICH  
10 HAPPENED ON JUNE 26TH, THE BOARD APPROVED A BUDGET  
11 ALLOCATION OF \$2 MILLION FOR LAUNCHING THE DISC2  
12 FUNDING OPPORTUNITY AND THEN ALSO AN ALLOCATION OF  
13 ALL REMAINING AND FUTURE UNALLOCATED RESEARCH FUNDS  
14 TO THE CLIN2 FUNDING OPPORTUNITY.

15 NOW, IN ORDER TO REALIZE THE  
16 IMPLEMENTATION OF THESE PROGRAMS AND TO OPEN THEM  
17 UP, WE ARE PROPOSING SOME CHANGES TO THE CONCEPT  
18 THAT WILL HELP ALIGN THEM WITH OUR OPERATIONAL  
19 TIMELINE THAT WE HAVE AND THE BUDGET THAT WAS  
20 ALLOCATED.

21 SO THIS IS A SUMMARY OF THE PROPOSED  
22 CHANGES TO THE DISC2 PROGRAM. AND AS MOST OF YOU  
23 KNOW, THE DISC2 SUPPORTS DISCOVERY-STAGE AWARDS. SO  
24 THESE ARE PROJECTS THAT ARE INTENDED TO IDENTIFY A  
25 CANDIDATE THERAPEUTIC, A MEDICAL DEVICE, A

**BETH C. DRAIN, CA CSR NO. 7152**

1 DIAGNOSTIC, OR A TOOL IN ORDER TO PREPARE THEM FOR  
2 FUTURE TRANSLATIONAL STUDIES.

3 NOW, THE CHANGES THAT WE ARE PROPOSING  
4 ALIGN WITH THE COVID-19 PROGRAM THAT WE HAD. SO WE  
5 ARE PROPOSING AN AWARD LIMIT OF 250,000 FOR TOTAL  
6 FUNDS REQUESTED WITH A MAXIMUM AWARD DURATION OF 12  
7 MONTHS. WE ALSO ARE SUGGESTING REDUCING THE PI  
8 PERCENT EFFORT REQUIREMENT FROM 20 PERCENT DOWN TO  
9 10 PERCENT GIVEN THIS MUCH SMALLER AWARD AMOUNT AND  
10 THE SHORTER DURATION. AND THEN WE SUGGEST THAT  
11 PROJECTS INITIATE WITHIN 30 DAYS OF APPROVAL DURING  
12 THE COVID-19 PROGRAM. THIS IS SOMETHING WE ALL GOT  
13 PRETTY GOOD AT HELPING TURN AROUND THESE PROJECTS  
14 AND ALSO THE APPLICANTS FROM VERY QUICKLY GETTING  
15 STARTED. SO GIVEN OUR TIMELINE, I THINK IT JUST  
16 MAKES SENSE TO HAVE A 30-DAY APPROVAL PERIOD FOR  
17 THESE COMPARED TO THE 120 DAYS THAT WE HAD IN THE  
18 PAST.

19 WE ARE ALSO GOING TO CARRY FORWARD A  
20 REQUIREMENT THAT WE BEGAN WITH THE COVID-19 PROGRAM,  
21 WHICH WAS TO HAVE APPLICANTS PROVIDE A STATEMENT  
22 THAT DESCRIBES HOW THEIR STUDY PLAN AND DESIGN HAS  
23 CONSIDERED THE INFLUENCE OF RACE, ETHNICITY, SEX  
24 AND GENDER DIVERSITY. AND SO THIS IS SOMETHING THAT  
25 HELPS US UNDERSTAND WHETHER THEY ARE THINKING ABOUT

**BETH C. DRAIN, CA CSR NO. 7152**

1 THESE ELEMENTS IN THEIR PROPOSAL WITH THE GOAL OF  
2 TRYING TO ENSURE THAT THEY ARE DEVELOPING  
3 THERAPEUTICS AND PRODUCTS THAT WILL ULTIMATELY BE  
4 AVAILABLE TO EVERYONE.

5 WE ARE ALSO NOTING THAT THE GWG AND THIS  
6 BOARD WILL CONSIDER THOSE STATEMENTS IN THEIR  
7 EVALUATIONS AND FUNDING RECOMMENDATIONS ALONG WITH  
8 GIVING PRIORITY TO THOSE THAT HAVE A GOOD PLAN FOR  
9 THOSE.

10 NOW, FOR THE CLIN2 PROGRAM, THE SUMMARY OF  
11 CHANGES THAT ARE PROPOSED ARE AS FOLLOWS: SO HERE  
12 WE ARE ADJUSTING THE AWARD LIMITS TO 5 PERCENT OF  
13 WHAT THEY USED TO BE. AND SO THOSE ARE SHOWN IN THE  
14 TABLE THAT WAS PROVIDED IN THE MEMO. AND SO THOSE  
15 ARE REDUCED NOW TO A RANGE OF 6 MILLION UP TO 11.25  
16 DEPENDING ON THE APPLICANT TYPE AND THE PHASE OR  
17 STAGE OF AWARD.

18 THE DURATION IS ALSO BEING ADJUSTED TO NOT  
19 EXCEED THREE YEARS AND AWARD COMPLETION NO LATER  
20 THAN NOVEMBER 2023. THIS IS IN ORDER TO ALIGN IT  
21 WITH THE FACT THAT BEYOND NOVEMBER 2023 WE WILL NOT  
22 BE ABLE TO MANAGE AWARDS, ASSUMING THAT WE DON'T  
23 HAVE CONTINUED FUNDING.

24 ALSO LIKE THE DISC2, WE ARE PROPOSING  
25 INITIATING PROJECTS WITHIN 30 DAYS OF APPROVAL TO

**BETH C. DRAIN, CA CSR NO. 7152**

1 GET THEM ON THEIR WAY. AND ALSO SIMILARLY, WE ARE  
2 IMPLEMENTING A REQUIREMENT FOR ALL APPLICANTS TO  
3 PROVIDE A WRITTEN PLAN IN THE APPLICATION FOR THEIR  
4 OUTREACH AND STUDY PARTICIPATION EFFORTS BY  
5 UNDERSERVED AND DISPROPORTIONATELY AFFECTED  
6 POPULATIONS.

7 IT IS IMPORTANT TO NOTE THAT THESE CHANGES  
8 FOR THE CLIN2 PROGRAM DO NOT APPLY TO THE SICKLE  
9 CELL DISEASE PROJECTS WHICH ARE FUNDED UNDER THE  
10 CIRM/NHLBI CURE SICKLE CELL DISEASE JOINT  
11 INITIATIVE. THOSE WILL CONTINUE AS BEFORE WITH THE  
12 ORIGINAL TIMELINES AND AWARD CAPS. THE ONLY  
13 ADDITION WOULD BE THE REQUIREMENT TO HAVE A PLAN FOR  
14 OUTREACH AND STUDY PARTICIPATION.

15 SO THE LAST SLIDE IS JUST SIMPLY A REQUEST  
16 FOR THE BOARD TO APPROVE THESE PROPOSED CHANGES SO  
17 THAT WE CAN MOVE THESE TWO PROGRAMS FORWARD. MR.  
18 CHAIRMAN.

19 CHAIRMAN THOMAS: THANK YOU, DR.  
20 SAMBRANO. I'D LIKE TO ENTERTAIN A MOTION THAT WE  
21 APPROVE BOTH CONCEPT PLANS. DO I HEAR SUCH A  
22 MOTION?

23 MR. JUELSGAARD: SO MOVED.

24 DR. DULIEGE: I SECOND.

25 CHAIRMAN THOMAS: MOVED BY

**BETH C. DRAIN, CA CSR NO. 7152**

1 MR. JUELSGAARD, SECONDED BY DR. DULIEGE. ANY  
2 DISCUSSION BY MEMBERS OF THE BOARD? HEARING NONE,  
3 ANY PUBLIC COMMENT? HEARING NONE, MARIA, WILL YOU  
4 PLEASE CALL THE ROLL.

5 MS. BONNEVILLE: SURE. GEORGE BLUMENTHAL.

6 DR. BLUMENTHAL: YES.

7 MS. BONNEVILLE: LINDA BOXER. ALLISON

8 BRASHEAR.

9 DR. BRASHEAR: YES.

10 MS. BONNEVILLE: DEBORAH DEAS.

11 DR. DEAS: YES.

12 MS. BONNEVILLE: ANNE-MARIE DULIEGE.

13 DR. DULIEGE: YES.

14 MS. BONNEVILLE: YSABEL DURON.

15 MS. DURON: YES.

16 MS. BONNEVILLE: JUDY GASSON.

17 DR. GASSON: YES.

18 MS. BONNEVILLE: DAVID HIGGINS.

19 DR. HIGGINS: YES.

20 MS. BONNEVILLE: STEPHEN JUELSGAARD.

21 MR. JUELSGAARD: YES.

22 MS. BONNEVILLE: LINDA MALKAS.

23 DR. MALKAS: YES.

24 MS. BONNEVILLE: DAVE MARTIN.

25 DR. MARTIN: YES.

**BETH C. DRAIN, CA CSR NO. 7152**

1 MS. BONNEVILLE: SHLOMO MELMED.  
2 DR. MELMED: YES.  
3 MS. BONNEVILLE: LAUREN MILLER-ROGEN.  
4 MS. MILLER-ROGEN: YES.  
5 MS. BONNEVILLE: ADRIANA PADILLA.  
6 DR. PADILLA: YES.  
7 MS. BONNEVILLE: JOE PANETTA.  
8 MR. PANETTA: YES.  
9 MS. BONNEVILLE: FRANCISCO PRIETO.  
10 DR. PRIETO: AYE.  
11 MS. BONNEVILLE: ROBERT QUINT. AL  
12 ROWLETT. SUZANNE SANDMEYER.  
13 DR. SANDMEYER: YES.  
14 MS. BONNEVILLE: JEFF SHEEHY.  
15 MR. SHEEHY: YES.  
16 MS. BONNEVILLE: OSWALD STEWARD. JONATHAN  
17 THOMAS.  
18 CHAIRMAN THOMAS: YES.  
19 MS. BONNEVILLE: ART TORRES.  
20 MR. TORRES: AYE.  
21 MS. BONNEVILLE: KRISTINA VUORI.  
22 DR. VUORI: YES.  
23 MS. BONNEVILLE: DIANE WINOKUR.  
24 MS. WINOKUR: YES.  
25 MS. BONNEVILLE: KEITH YAMAMOTO. DOUG

**BETH C. DRAIN, CA CSR NO. 7152**

1 ZIEDONIS.

2 DR. ZIEDONIS: YES.

3 MS. BONNEVILLE: THANK YOU. THE MOTION  
4 CARRIES.

5 CHAIRMAN THOMAS: THANK YOU, MARIA, AND  
6 THANK YOU, DR. SAMBRANO AND TEAM, FOR YOUR WORK AS  
7 ALWAYS ON THE PRESENTATION FOR THIS ITEM.

8 THE NEXT ACTION ITEM IS APPOINTMENT AND  
9 REAPPOINTMENT OF SCIENTIFIC MEMBERS TO THE GWG. I  
10 BELIEVE YOU RECEIVED INFORMATION ON THIS ITEM. DO I  
11 HEAR A MOTION TO APPROVE?

12 MS. WINOKUR: I MOVE.

13 CHAIRMAN THOMAS: THANK YOU, DIANE.

14 DR. MARTIN: SECOND.

15 CHAIRMAN THOMAS: THANK YOU, DAVE. IT'S  
16 BEEN MOVED BY MS. WINOKUR, SECONDED BY DR. MARTIN.  
17 IS THERE ANY DISCUSSION BY MEMBERS OF THE BOARD?  
18 ANY DISCUSSION BY MEMBERS OF THE PUBLIC?

19 MS. BONNEVILLE: THERE ARE NO HANDS  
20 RAISED.

21 CHAIRMAN THOMAS: THANK YOU. HEARING  
22 NONE, MARIA, WILL YOU PLEASE CALL THE ROLL.

23 MS. BONNEVILLE: SURE. GEORGE BLUMENTHAL.

24 DR. BLUMENTHAL: YES.

25 MS. BONNEVILLE: LINDA BOXER. ALLISON

**BETH C. DRAIN, CA CSR NO. 7152**

1 BRASHEAR.  
2 DR. BRASHEAR: YES.  
3 MS. BONNEVILLE: DEBORAH DEAS.  
4 DR. DEAS: YES.  
5 MS. BONNEVILLE: ANNE-MARIE DULIEGE.  
6 DR. DULIEGE: YES.  
7 MS. BONNEVILLE: YSABEL DURON.  
8 MS. DURON: YES.  
9 MS. BONNEVILLE: JUDY GASSON.  
10 DR. GASSON: YES.  
11 MS. BONNEVILLE: DAVID HIGGINS.  
12 DR. HIGGINS: YES.  
13 MS. BONNEVILLE: STEPHEN JUELSGAARD.  
14 MR. JUELSGAARD: YES.  
15 MS. BONNEVILLE: LINDA MALKAS.  
16 DR. MALKAS: YES.  
17 MS. BONNEVILLE: DAVE MARTIN.  
18 DR. MARTIN: YES.  
19 MS. BONNEVILLE: SHLOMO MELMED.  
20 DR. MELMED: YES.  
21 MS. BONNEVILLE: LAUREN MILLER-ROGEN.  
22 MS. MILLER-ROGEN: YES.  
23 MS. BONNEVILLE: ADRIANA PADILLA.  
24 DR. PADILLA: YES.  
25 MS. BONNEVILLE: JOE PANETTA.

**BETH C. DRAIN, CA CSR NO. 7152**

1 MR. PANETTA: YES.  
2 MS. BONNEVILLE: FRANCISCO PRIETO.  
3 DR. PRIETO: AYE.  
4 MS. BONNEVILLE: ROBERT QUINT. AL  
5 ROWLETT. SUZANNE SANDMEYER.  
6 DR. SANDMEYER: YES.  
7 MS. BONNEVILLE: JEFF SHEEHY.  
8 MR. SHEEHY: YES.  
9 MS. BONNEVILLE: OSWALD STEWARD. JONATHAN  
10 THOMAS.  
11 CHAIRMAN THOMAS: YES.  
12 MS. BONNEVILLE: ART TORRES.  
13 MR. TORRES: AYE.  
14 MS. BONNEVILLE: KRISTINA VUORI.  
15 DR. VUORI: YES.  
16 MS. BONNEVILLE: DIANE WINOKUR.  
17 MS. WINOKUR: YES.  
18 MS. BONNEVILLE: KEITH YAMAMOTO. DOUG  
19 ZIEDONIS.  
20 DR. ZIEDONIS: YES.  
21 MS. BONNEVILLE: THANK YOU. THE MOTION  
22 CARRIES.  
23 CHAIRMAN THOMAS: THANK YOU, MARIA. THAT  
24 CONCLUDES THE ACTION ITEMS ON THE AGENDA. WE HAVE A  
25 COUPLE OF DISCUSSION ITEMS, ONE OF PARTICULAR

**BETH C. DRAIN, CA CSR NO. 7152**

1 SUBSTANCE, WHICH IS UPDATE ON DONATIONS RECEIVED BY  
2 CIRM.

3 FROM TIME TO TIME, YOU MAY KNOW THAT WE  
4 GET DONATIONS FROM VARIOUS SOURCES FOR DIFFERENT  
5 PARTICULAR ITEMS AT CIRM AND ARE ALWAYS GRATEFUL TO  
6 GET THOSE. AS IT HAPPENS JUNE 30 WAS A BIG DAY. WE  
7 RECEIVED TWO CONTRIBUTIONS THAT DAY. THE FIRST WAS  
8 FROM AN ESTATE, WHICH IS VERY NICE, OF A WOMAN NAMED  
9 LIVIA M. LUXE WHO HAD FOR CIRM AN AMOUNT OF  
10 \$270,602.57, WHICH WE WERE VERY GRATEFUL TO RECEIVE.

11 THE SECOND WAS, AS YOU MAY RECALL, SEVERAL  
12 YEARS AGO BILL BOWES PLEDGED TO GIVE CIRM A TOTAL OF  
13 \$5 MILLION TO HELP COVER ADMINISTRATIVE EXPENSES,  
14 AND THAT GIFT WAS SPLIT UP INTO TWO EQUAL PARTS OF  
15 TWO AND A HALF MILLION. THE FIRST WAS RECEIVED A  
16 YEAR PLUS AGO, THE SECOND TWO AND A HALF MILLION WAS  
17 RECEIVED A JUNE 30TH. WE ARE OBVIOUSLY VERY  
18 GRATEFUL TO RECEIVE THAT.

19 AND AS IS OUR PRACTICE, HAVE SENT OUT OUR  
20 DONATION ACKNOWLEDGEMENT LETTERS AND PROFUSELY  
21 THANKED THE FAMILIES OF BOTH AND THE FOUNDATION IN  
22 MR. BOWES' CASE FOR THEIR GENEROUS CONTRIBUTIONS.  
23 ANY QUESTIONS ABOUT THOSE?

24 MR. TORRES: CAN ANY OF THAT MONEY BE USED  
25 FOR OUR COVID EXPANSION?

**BETH C. DRAIN, CA CSR NO. 7152**

1                   CHAIRMAN THOMAS:   WELL, I DON'T -- THE  
2 LIVIA LUXE I DON'T BELIEVE HAD ANY RESTRICTIONS ON  
3 IT.   SO I BELIEVE IT CAN BE.

4                   MR. TORRES:   OKAY.

5                   CHAIRMAN THOMAS:   THE BOWES GIFT WAS  
6 TARGETED SPECIFICALLY FOR ADMINISTRATIVE EXPENSES.

7                   ANY OTHER QUESTIONS?   OKAY.   HEARING NONE,  
8 THE LAST ITEM ON THE AGENDA IS PUBLIC COMMENT ON ANY  
9 TOPIC THAT ANYBODY WOULD LIKE TO SPEAK ABOUT.   DO WE  
10 HAVE ANY PUBLIC COMMENT?   HERE NONE, THAT CONCLUDES  
11 TODAY'S MEETING.

12                   I WANT TO THANK EVERYBODY FOR MAKING  
13 YOURSELVES AVAILABLE.   I KNOW WE'VE HAD AN AWFUL LOT  
14 OF BOARD MEETINGS OVER THE LAST TWO OR THREE MONTHS.  
15 WE HAVE OUR NEXT ONE THIS FRIDAY AT 4 P.M., WHICH IS  
16 THE BOARD AND APPLICATION REVIEW SUBCOMMITTEE TO  
17 CONSIDER PROJECTS RECOMMENDED FOR FUNDING AT  
18 YESTERDAY'S GWG.   SO HOPE TO SEE YOU THERE.   AND  
19 WITHOUT FURTHER ADO, WE STAND ADJOURNED.

20                   MS. BONNEVILLE:   THANK YOU, EVERYONE.  
21 APPRECIATE IT.

22                   (THE MEETING WAS THEN CONCLUDED AT  
23 1:23 P.M.)

24  
25

**REPORTER'S CERTIFICATE**

I, BETH C. DRAIN, A CERTIFIED SHORTHAND REPORTER IN AND FOR THE STATE OF CALIFORNIA, HEREBY CERTIFY THAT THE FOREGOING TRANSCRIPT OF THE ZOOM PROCEEDINGS BEFORE THE INDEPENDENT CITIZEN'S OVERSIGHT COMMITTEE AND THE APPLICATION REVIEW SUBCOMMITTEE OF THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE IN THE MATTER OF ITS REGULAR MEETING HELD ON JULY 22, 2020, WAS HELD AS HEREIN APPEARS AND THAT THIS IS THE ORIGINAL TRANSCRIPT THEREOF AND THAT THE STATEMENTS THAT APPEAR IN THIS TRANSCRIPT WERE REPORTED STENOGRAPHICALLY BY ME AND TRANSCRIBED BY ME. I ALSO CERTIFY THAT THIS TRANSCRIPT IS A TRUE AND ACCURATE RECORD OF THE PROCEEDING.

BETH C. DRAIN, CA CSR 7152  
133 HENNA COURT  
SANDPOINT, IDAHO  
(208) 255-5453